Seres Therapeutics Inc. (MCRB:NASDAQ); November 10, 2021 (Wednesday) placeholder

US DEA OKs Use of Psychedelics by This Mental Health Network
Source: Streetwise Reports (11/09/2021)

Clinics that deliver novel psychiatric treatment and host clinical trials of psychedelic medicine have positioned Novamind for breakthroughs in mental health treatment.

read more >

Programmed T Cell Therapies Co. Receives $250M Investment From Blackstone to Advance Adult Leukemia Treatment
Source: Streetwise Reports (11/08/2021)

Autolus Therapeutics Plc. shares traded 28% higher after the company reported that Blackstone Life Sciences is investing up to $250 million in the firm to develop obe-cel in treatment of adult Acute Lymphoblastic Leukemia and advance its broader targeted T- Cell technology platform.

read more >

Key Data Readouts Expected in 2022 for Developer of Cancer Immunotherapies
Source: Streetwise Reports (11/08/2021)

Results expected are for trials of Jounce Therapeutics' two lead product candidates, vopratelimab and pimivalimab, both monoclonal antibodies, noted a ROTH Capital Partners report.

read more >

Specialty Pharma Co. Increases Revenues by 22% in Q3; Raises FY Sales and Earnings Forecast
Source: Streetwise Reports (11/05/2021)

Shares of brand, generic and injectable drug maker Endo International traded 25% higher after the company reported Q3/21 financial results and raised its FY/21 revenue and EPS guidance.

read more >

Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands
Source: McAlinden Research for Streetwise Reports (11/03/2021)

McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom.

read more >